refactor(asl): ASL frontend architecture refactoring with left navigation
- feat: Create ASLLayout component with 7-module left navigation - feat: Implement Title Screening Settings page with optimized PICOS layout - feat: Add placeholder pages for Workbench and Results - fix: Fix nested routing structure for React Router v6 - fix: Resolve Spin component warning in MainLayout - fix: Add QueryClientProvider to App.tsx - style: Optimize PICOS form layout (P+I left, C+O+S right) - style: Align Inclusion/Exclusion criteria side-by-side - docs: Add architecture refactoring and routing fix reports Ref: Week 2 Frontend Development Scope: ASL module MVP - Title Abstract Screening
This commit is contained in:
@@ -0,0 +1,186 @@
|
||||
# LLM筛选质量测试报告
|
||||
|
||||
**测试时间**: 2025-11-18T08:10:57.409Z
|
||||
**测试模型**: deepseek-chat + qwen-max
|
||||
**测试样本数**: 10
|
||||
|
||||
---
|
||||
|
||||
## 质量指标
|
||||
|
||||
| 指标 | 实际值 | 目标值 | 状态 |
|
||||
|------|--------|--------|------|
|
||||
| 准确率 | 60.0% | ≥85% | ❌ |
|
||||
| 一致率 | 70.0% | ≥80% | ❌ |
|
||||
| 平均置信度 | 0.95 | - | - |
|
||||
| 需人工复核率 | 30.0% | ≤20% | ❌ |
|
||||
|
||||
---
|
||||
|
||||
## 混淆矩阵
|
||||
|
||||
```
|
||||
预测纳入 预测排除 不确定
|
||||
实际纳入 2 1 -
|
||||
实际排除 0 4 -
|
||||
不确定 - - 0
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 详细结果
|
||||
|
||||
|
||||
### 1. test-001
|
||||
|
||||
**标题**: Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
|
||||
**期望决策**: include
|
||||
**实际决策**: exclude
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.93
|
||||
**处理时间**: 11935ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.90)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 2. test-002
|
||||
|
||||
**标题**: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
|
||||
**期望决策**: include
|
||||
**实际决策**: include
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13225ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: include (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
### 3. test-003
|
||||
|
||||
**标题**: Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 10683ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 4. test-004
|
||||
|
||||
**标题**: Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13067ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 5. test-005
|
||||
|
||||
**标题**: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|
||||
**期望决策**: include
|
||||
**实际决策**: include
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12352ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: include (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
### 6. test-006
|
||||
|
||||
**标题**: Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 11690ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 7. test-007
|
||||
|
||||
**标题**: Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers
|
||||
**期望决策**: exclude
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 14253ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 8. test-008
|
||||
|
||||
**标题**: Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes
|
||||
**期望决策**: exclude
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12808ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 9. test-009
|
||||
|
||||
**标题**: Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report
|
||||
**期望决策**: exclude
|
||||
**实际决策**: exclude
|
||||
**结果**: ✅ 正确
|
||||
**一致性**: ✅ 一致
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 12092ms
|
||||
**需人工复核**: 否
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: exclude (置信度: 0.95)
|
||||
|
||||
|
||||
### 10. test-010
|
||||
|
||||
**标题**: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment
|
||||
**期望决策**: uncertain
|
||||
**实际决策**: pending
|
||||
**结果**: ❌ 错误
|
||||
**一致性**: ❌ 冲突
|
||||
**平均置信度**: 0.95
|
||||
**处理时间**: 13503ms
|
||||
**需人工复核**: 是
|
||||
|
||||
**DeepSeek结论**: exclude (置信度: 0.95)
|
||||
**Qwen结论**: include (置信度: 0.95)
|
||||
|
||||
|
||||
---
|
||||
|
||||
**生成时间**: 2025-11-18T08:10:57.409Z
|
||||
Reference in New Issue
Block a user